Fluticasone Propionate/Azelastine (Dymista)
Is It Right for You?
A complete guide to Fluticasone Propionate/Azelastine (Dymista) — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Dymista?
Dymista is a combination intranasal spray delivering fluticasone propionate 50 micrograms (a potent intranasal corticosteroid) and azelastine hydrochloride 137 micrograms (a second-generation antihistamine) per actuation. It is the first and only licensed fixed-dose combination intranasal ICS/antihistamine product available in the UK, delivering both a corticosteroid and an antihistamine directly to the nasal mucosa simultaneously in a single spray.
This dual-agent approach addresses both the early-phase IgE-mediated histamine response (treated by azelastine) and the late-phase, predominantly eosinophilic inflammatory response (treated by fluticasone) that together produce the full spectrum of allergic rhinitis symptoms. Clinical trials have consistently demonstrated that Dymista provides superior symptom control compared to either fluticasone or azelastine nasal sprays used alone — with significantly faster symptom relief and better overall nasal and ocular symptom scores.
Dymista is a prescription-only medication in the UK. A clinician must confirm the diagnosis of moderate-to-severe allergic rhinitis and confirm that treatment step-up beyond individual monotherapy is clinically appropriate.
What Conditions Is Dymista Used For?
Dymista is indicated for:
treatment of moderate-to-severe SAR (hay fever) in adults and adolescents aged 12 years and over whose symptoms are not adequately controlled by intranasal corticosteroid or antihistamine monotherapy alone
treatment of year-round allergic rhinitis caused by persistent allergens (house dust mite, animal dander) where step-up combination therapy is indicated
azelastine has systemic absorption from the nasal mucosa that contributes to relief of allergic conjunctivitis symptoms, providing some benefit beyond purely nasal symptom control
Dymista is licensed specifically for patients whose allergic rhinitis symptoms are not adequately controlled by intranasal corticosteroid monotherapy or antihistamine monotherapy alone. It provides a convenient single-spray option that replaces the need to use two separate intranasal preparations. It is not a first-line treatment for mild allergic rhinitis, where a single intranasal corticosteroid alone is the recommended first approach.
How Does Dymista Work?
Dymista's superior efficacy over monotherapy reflects the complementary actions of its two active components on different phases of the allergic response:
Fluticasone propionate (intranasal ICS): Fluticasone propionate binds to glucocorticoid receptors in nasal mucosal epithelial cells, mast cells, eosinophils, and macrophages, suppressing the late-phase allergic inflammatory response. It reduces the production of inflammatory cytokines, decreases eosinophil recruitment and survival, reduces mucosal oedema, and attenuates nasal hyperresponsiveness. These effects predominantly address nasal congestion, persistent rhinorrhoea, and the late-phase nasal inflammatory response. Its systemic bioavailability from intranasal use is <0.5%, resulting in minimal systemic corticosteroid exposure.
Azelastine hydrochloride (intranasal antihistamine): Azelastine is a potent, second-generation histamine H1 receptor antagonist with rapid onset of action when delivered intranasally — typically within 15 minutes. It blocks histamine-mediated early-phase allergic symptoms including nasal itch, sneezing, and watery rhinorrhoea directly at the nasal mucosal surface. In addition to H1 blockade, azelastine has mast cell stabilising properties and inhibits
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Prime the pump before first use by pressing the actuator firmly 6 times until a fine mist appears. Re-prime with 2 pumps if not used for more than 3 days.
Correct nasal spray technique is essential. Blow the nose gently before use. Hold the bottle upright, tilt the head slightly forward, insert the nozzle gently into one nostril pointing toward the outer wall of the nose (away from the nasal septum), and spray while breathing in gently through the nose. Avoid sniffing hard — the drug should remain in the nose, not travel to the back of the throat.
Avoid spraying toward the nasal septum. Directing the spray toward the nasal septum increases the risk of septal irritation and, rarely, septal perforation with long-term intranasal corticosteroid use.
Do not exceed one spray per nostril twice daily. More frequent dosing does not improve efficacy and increases the risk of epistaxis and local side effects.
Wipe the nozzle clean after each use and replace the cap to prevent contamination.
Side Effects of Dymista
Most side effects are mild and resolve on their own. Serious side effects are rare but require immediate medical attention.
- Epistaxis (nosebleed) --- the most common local adverse effect of intranasal corticosteroid use; usually mild; risk is reduced by correct spray technique directed away from the septum
- Nasal burning or stinging on application --- from the azelastine component; usually transient
- Dysgeusia (bitter or unpleasant taste) --- characteristic of azelastine nasal sprays; caused by postnasal drainage; tilting the head slightly forward during use and avoiding deep sniffing reduces taste disturbance
- Headache
- Nasal dryness
- Nasal septal perforation --- rare; associated with chronic intranasal corticosteroid use; persistent nasal crusting, bleeding, or whistling during breathing requires ENT assessment
- Glaucoma and cataracts --- rare; associated with long-term high-dose intranasal corticosteroid use, particularly with incorrect technique directing spray toward the medial nasal wall near the inner canthus
- HPA axis suppression --- clinically very unlikely at recommended intranasal doses of fluticasone propionate due to
- Severe hypersensitivity reactions --- rare
The most important aspect of safe long-term intranasal corticosteroid use is directing the spray toward the lateral nasal wall, away from the nasal septum. Incorrect technique repeatedly directing the spray toward the septum is the principal cause of nasal septal irritation, ulceration, and — in rare cases — perforation. Patients must be trained in correct technique at initiation and rechecked at review.
Drug Interactions
Always disclose all prescription drugs, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting Dymista
even intranasal fluticasone propionate can have its systemic levels increased significantly by potent CYP3A4 inhibitors, particularly ritonavir, which has been associated with Cushing's syndrome and adrenal suppression; avoid concurrent use where possible.
azelastine's systemic absorption from intranasal use is limited but not zero; at standard doses, CNS-depressant effects are minimal; theoretical additive sedation with other CNS depressants; advise caution with alcohol.
multiple intranasal preparations should not be used in the same nostril at the same time; allow several minutes between different nasal sprays if more than one is prescribed.
Important Warnings
Dymista must be directed toward the outer (lateral) nasal wall, not the nasal septum. Chronic spraying toward the septum is the primary risk factor for nasal septal ulceration and perforation with intranasal corticosteroid use. Demonstrate and recheck technique at every clinical review.
Dymista is licensed for adults and adolescents aged 12 years and over. It is not appropriate for use in children under 12 without specialist guidance.
Although intranasal fluticasone has very low systemic bioavailability, long-term use should be reviewed periodically to confirm ongoing clinical benefit and to assess for local side effects. For perennial allergic rhinitis, annual review is recommended.
Intranasal corticosteroids are generally preferred over oral antihistamines for allergic rhinitis in pregnancy due to low systemic absorption. The combination product Dymista should be used during pregnancy only when the benefit clearly outweighs the risk; discuss with your clinician. Intranasal azelastine has very limited published safety data in pregnancy.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Dymista FAQs
Dymista is prescribed when a single intranasal preparation is not providing adequate symptom control. By combining a corticosteroid (fluticasone) and an antihistamine (azelastine) in a single spray, it addresses both the early histamine-mediated symptoms (sneezing, itch, watery rhinorrhoea) and the later inflammatory phase (congestion, persistent rhinorrhoea) more comprehensively than either agent alone. Clinical trials show it provides significantly better overall symptom control than monotherapy.
Yes. A bitter or unpleasant taste is a characteristic and very common side effect of azelastine nasal sprays, caused by drug solution draining through the nasolacrimal duct into the throat. Minimising this by tilting the head slightly forward during use and sniffing gently (not hard) after spraying helps keep more drug in the nose. The taste is harmless and typically lasts only a few minutes.
Azelastine provides fast relief — typically within 15 minutes of spraying — for sneezing, itch, and watery rhinorrhoea. Fluticasone's anti-inflammatory effects build up over several days of regular use. For maximum benefit, use Dymista consistently every day throughout your allergy season rather than only on symptomatic days.
Dymista already contains the antihistamine azelastine delivered intranasally. Adding an oral antihistamine provides some marginal additional systemic antihistamine effect for eye symptoms, but there is limited evidence of meaningful additional benefit for nasal symptoms. Discuss with your clinician whether a combined oral and intranasal approach is appropriate for you, particularly if eye symptoms are prominent.
For the best results during allergy season, regular daily use is recommended. Fluticasone's anti-inflammatory benefit accumulates with consistent use and works best when maintained rather than started reactively. Azelastine provides immediate symptom relief. Using both components consistently provides a more stable level of symptom control than reactive use only on bad days.